Dallas Venture Deals

September 2023

Howdy!

Welcome to the third edition of the Dallas Venture Deals newsletter! We are grateful for the responses, feedback, and engagement. Our goal remains simple: shine a spotlight on DFW’s venture capital activity, in a region where remarkable transactions often go unnoticed. Cheers to the future of DFW startups!

Venture Deals

DFW-Based Company Fundings - September

DFW-Based Investor Transactions - September

  • AOA Capital Partners (Southlake, TX) participated in $5.5M Series A for Enhans (Seoul, South Korea), an AI commerce solutions startup, alongside Hyundai Technology Investment, L&S Venture Capital,  KDB Saneun Capital, and Timefolio Asset Management.

  • Avidity Partners (Dallas, TX) exited its investment in Dianthus Therapeutics (Waltham, MA), a privately-held clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics, in merger with Magenta Therapeutics, alongside prev. investors Wedbush Capital Partners, Catalio Capital Management, Tellus BioVentures, Venrock, 5AM Ventures, Fidelity Investments, and Fairmount Partners.

  • Beyond Capital Ventures (Dallas, TX) invested in Series A for Ampersand (Kigali, Rwanda), Africa’s first and leading integrated electric motorcycle and transport energy solution.

  • BP Energy Partners (Dallas, TX) sponsored Encino Environmental Services’ acquisition of SENSIA (Madrid, ES), a market leader in cutting-edge solutions based on advanced infrared (IR) imaging technology and A.I., additional sponsors include EnCap Investments and Williams New Energy Ventures.

  • Colt Ventures (Dallas, TX) and Hunt Technology Investors (Dallas, TX) co-invested in $260M Series B for ReCode Therapeutics (Menlo Park, CA), a clinical-stage genetic medicines company. The round was led by Pfizer Ventures, Leaps by Bayer and Matrix Capital Management, and included participation from Sanofi Ventures, Timefolio Capital, Amgen Ventures, OrbiMed, MPM Capital, Vida Ventures (Boston), Osage University Partners, EcoR1 Capital, Paratus Investment, Ayur Maya, Bioluminescence Ventures, Solasta Ventures, Tekla Capital Management, Superstring Capital Management, and Cystic Fibrosis Foundation.

  • Concorde Investment Management (Dallas, TX) and Omnimed Capital (Dallas, TX) co-invested in $100M Series B for Pryon, the pioneer in bringing AI to knowledge management. The round was led by Thomas Tull’s US Innovative Technology Fund, and included participation from Aperture Venture Capital, BootstrapLabs, Breyer Capital, Duke Capital Partners, Good Growth Capital, Revolution’s Rise of the Rest Seed Fund, and others.

  • Dallas Venture Capital (Irving, TX), participated in $6M seed round for Pynt (Tel Aviv, Israel), a provider of an autopilot platform for API security. The round was led by Joule Ventures with additional participation from Honey Stone VC.

  • Fund Formation Group (Dallas, TX), a firm launching and operating fund structures for RIAs and wealth advisors, has been acquired by GLASFunds (Cleveland, OH).

  • Perot Jain (Dallas, TX) participated in $20M Series A for Testfit (Dallas, TX), a  real estate feasibility platform for developers, architects, and contractors. The round was co-led by Prologis Ventures and Parkway Venture Capital.

Dallas Venture Tracker

DFW-Startups | Capital Invested & Deal Count

Dallas Venture Key Hires

Dallas Venture Events

Other Dallas Venture News

Dallas Venture Resources

Make sure we know about your company’s upcoming transaction

Make sure we know about your upcoming venture ecosystem event

Did someone forward you this email?

Want to view prior deal summaries?

Brought to you by Aaron Pierce & Jonathan FineSupported by Perot JainCopyright (C) " target="_blank">unsubscribe

Keep reading

No posts found